With $30M In Hand, Zosano Hopes Its Osteoporosis Patch Will Compete With Forteo
This article was originally published in The Pink Sheet Daily
Executive SummaryDespite a long list of potential therapeutic uses for its transdermal patch technology, privately held biotech seeks direct competition in osteoporosis anabolic therapy space.
You may also be interested in...
Janssen licenses a rheumatoid arthritis program from Modern Biosciences that could address the inflammatory and bone-destruction manifestations of the disease, while Japan’s Otsuka buys Avanir on the strength of its neuroscience pipeline. Meanwhile, previously signed Astellas/Janssen and Novartis/Array agreements are terminated.